← Eichor
Condition: Macular Abnormalities Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Macular Abnormalities

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degener
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT06375239NEPTUNE Match Study
NA · 16 location(s) · University of Michigan · NCT04571658An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease
EARLY_Phase 1 · 1 location(s) · HuidaGene Therapeutics Co., Ltd. · NCT07063251Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Phase N/A · 8 location(s) · Ascidian Therapeutics, Inc · NCT06445322Phase 1 Study of C.001 in Retinal Degeneration
Phase 1 · 1 location(s) · Cellio Therapeutics Inc · NCT07594236(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NA · 6 location(s) · Carl Zeiss Meditec-Dublin CoCe · NCT07680244Cell Collection to Study Eye Diseases
Phase N/A · 1 location(s) · National Eye Institute (NEI) · NCT01432847Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Phase 1/Phase 2 · 10 location(s) · Ascidian Therapeutics, Inc · NCT06467344Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients
Phase 1/Phase 2 · 3 location(s) · Ray Therapeutics, Inc. · NCT07439887Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal
Phase N/A · 1 location(s) · Ray Therapeutics, Inc. · NCT07502664A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
Phase 1/Phase 2 · 8 location(s) · AAVantgarde Bio Srl · NCT07161544Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · 47 location(s) · Travere Therapeutics, Inc. · NCT05003986An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Au
Phase N/A · 20 location(s) · Splice Bio · NCT06435000Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies
Phase 1/Phase 2 · 2 location(s) · Ace Cells Lab Limited · NCT06787482A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Phase N/A · 12 location(s) · Astellas Pharma Global Development, Inc. · NCT07425574Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Phase 1 · 2 location(s) · The Foundation for Orthopaedics and Regenerative Medicine · NCT05147701National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and
Phase N/A · 2 location(s) · National Eye Institute (NEI) · NCT06491615Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease
Phase 1/Phase 2 · 1 location(s) · VeonGen Therapeutics GmbH · NCT07002398Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) o
Phase 1/Phase 2 · 4 location(s) · Opus Genetics, Inc · NCT07185256Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Phase N/A · 1 location(s) · Hadassah Medical Organization · NCT00874783Imaging Retinal Vasculature in Infant Eyes
Phase N/A · 2 location(s) · Duke University · NCT05558059Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
Phase 1 · 5 location(s) · Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Far · NCT06395285A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficac
Phase 1/Phase 2 · 5 location(s) · Splice Bio · NCT06942572Study of BEST1 Vitelliform Macular Dystrophy
Phase N/A · 3 location(s) · Columbia University · NCT05809635Study of ALK-001 on the Progression of Stargardt Disease
Phase 3 · 5 location(s) · Alkeus Pharmaceuticals, Inc. · NCT07419334Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration
NA · 1 location(s) · Science Corporation · NCT07266584High Resolution Retinal Imaging
Phase N/A · 1 location(s) · University of Pennsylvania · NCT01866371Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
Phase 4 · 1 location(s) · Faculty Hospital Kralovske Vinohrady · NCT06875245High Resolution, High-speed Multimodal Ophthalmic Imaging
NA · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT04129021A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
NA · 1 location(s) · Oculox Technologies SA · NCT06557369
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.